No overt structural or functional changes associated with PEG-coated gold nanoparticles accumulation with acute exposure in the mouse heart

Toxicology Letters

Volumn 222, Issue 2, 2013, Pages 197-203

  Yang, Chengzhi ^a   Yang, Hui ^b   Wu, Jimin ^a   Meng, Zenghui ^a   Xing, Rui ^a   Tian, Aiju ^a   Tian, Xin ^b   Guo, Lijun ^a   Zhang, Youyi ^a   Nie, Guangjun ^b   Li, Zijian ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

Author keywords

Cardiac remodeling; Cardiac toxicity; Gold nanoparticles; Heart

Indexed keywords

EOSIN; GOLD NANOPARTICLE; HEMATOXYLIN; ISOPRENALINE; MACROGOL; NANOCOATING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDITIS; CELL STRUCTURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EXPOSURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STRUCTURE ANALYSIS; TISSUE DISTRIBUTION;

CARDIAC REMODELING; CARDIAC TOXICITY; GOLD NANOPARTICLES; HEART;

ADRENERGIC BETA-AGONISTS; ANIMALS; CARDIOMEGALY; CARDIOTOXINS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FIBROSIS; GOLD; HEART VENTRICLES; ISOPROTERENOL; MALE; METAL NANOPARTICLES; MICE; MICE, INBRED BALB C; POLYETHYLENE GLYCOLS; RANDOM ALLOCATION; SURFACE PROPERTIES; TISSUE DISTRIBUTION; VENTRICULAR FUNCTION; VENTRICULAR REMODELING;

EID: 84882973891     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.07.018     Document Type: Article

References (29)

1. Abdelhalim M.A. Gold nanoparticles administration induces disarray of heart muscle, hemorrhagic, chronic inflammatory cells infiltrated by small lymphocytes, cytoplasmic vacuolization and congested and dilated blood vessels. Lipids in Health and Disease 2011, 10:233.
2. Cho W.S., Cho M., Jeong J., Choi M., Cho H.Y., Han B.S., Kim S.H., Kim H.O., Lim Y.T., Chung B.H., Jeong J. Acute toxicity and pharmacokinetics of 13nm-sized PEG-coated gold nanoparticles. Toxicology and Applied Pharmacology 2009, 236:16-24.
3. Connor E.E., Mwamuka J., Gole A., Murphy C.J., Wyatt M.D. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 2005, 1:325-327.
4. Davel A.P., Fukuda L.E., De Sa L.L., Munhoz C.D., Scavone C., Sanz-Rosa D., Cachofeiro V., Lahera V., Rossoni L.V. Effects of isoproterenol treatment for 7 days on inflammatory mediators in the rat aorta. American Journal of Physiology Heart and Circulatory Physiology 2008, 295:H211-H219.
5. De Jong W.H., Hagens W.I., Krystek P., Burger M.C., Sips A.J., Geertsma R.E. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008, 29:1912-1919.
6. Dreaden E.C., Austin L.A., Mackey M.A., El-Sayed M.A. Size matters: gold nanoparticles in targeted cancer drug delivery. Therapeutic Delivery 2012, 3:457-478.
7. Duncan B., Kim C., Rotello V.M. Gold nanoparticle platforms as drug and biomacromolecule delivery systems. Journal of Controlled Release 2010, 148:122-127.
8. Frens G. Controlled nucleation for the regulation of the particle size in monodisperse gold suspensions. Nature Physical Science 1973, 241:20-22.
9. Frey N., Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annual Review of Physiology 2003, 65:45-79.
10. Gunter C., Dhand R. Human biology by proxy. Nature 2002, 420:509.
11. Huang W.Y., Qian W., Jain P.K., El-Sayed M.A. The effect of plasmon field on the coherent lattice phonon oscillation in electron-beam fabricated gold nanoparticle pairs. Nano Letters 2007, 7:3227-3234.
12. Iversen N.K., Nielsen A.R., Wang T., Baatrup E. Intravascular infusion of PEGylated Au nanoparticles affects cardiovascular function in healthy mice. Human & Experimental Toxicology 2013, 32:216-221.
13. Jeong K., Kwon H., Min C., Pak Y. Modulation of the caveolin-3 localization to caveolae and STAT3 to mitochondria by catecholamine-induced cardiac hypertrophy in H9c2 cardiomyoblasts. Experimental & Molecular Medicine 2009, 41:226-235.
14. Khlebtsov N., Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chemical Society Reviews 2011, 40:1647-1671.
15. Lasagna-Reeves C., Gonzalez-Romero D., Barria M.A., Olmedo I., Clos A., Sadagopa R.V., Urayama A., Vergara L., Kogan M.J., Soto C. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochemical and Biophysical Research Communications 2010, 393:649-655.
16. Lee S., Kim M.S., Lee D., Kwon T.K., Khang D., Yun H.S., Kim S.H. The comparative immunotoxicity of mesoporous silica nanoparticles and colloidal silica nanoparticles in mice. International Journal of Nanomedicine 2013, 8:147-158.
17. Liu A., Ye B. Application of gold nanoparticles in biomedical researches and diagnosis. Clinical Laboratory 2013, 59:23-36.
18. Male K.B., Lachance B., Hrapovic S., Sunahara G., Luong J.H. Assessment of cytotoxicity of quantum dots and gold nanoparticles using cell-based impedance spectroscopy. Analytical Chemistry 2008, 80:5487-5493.
19. Murray D.R., Prabhu S.D., Chandrasekar B. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000, 101:2338-2341.
20. Oberdorster G., Oberdorster E., Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environmental Health Perspectives 2005, 113:823-839.
21. Patten R.D., Hall-Porter M.R. Small animal models of heart failure: development of novel therapies, past and present. Circulation: Heart Failure 2009, 2:138-144.
22. Pernodet N., Fang X., Sun Y., Bakhtina A., Ramakrishnan A., Sokolov J., Ulman A., Rafailovich M. Adverse effects of citrate/gold nanoparticles on human dermal fibroblasts. Small 2006, 2:766-773.
23. Prabhu P., Patravale V. The upcoming field of theranostic nanomedicine: an overview. Journal of Biomedical Nanotechnology 2012, 8:859-882.
24. Rusyn I., Gatti D.M., Wiltshire T., Kleeberger S.R., Threadgill D.W. Toxicogenetics: population-based testing of drug and chemical safety in mouse models. Pharmacogenomics 2010, 11:1127-1136.
25. Sadauskas E., Wallin H., Stoltenberg M., Vogel U., Doering P., Larsen A., Danscher G. Kupffer cells are central in the removal of nanoparticles from the organism. Particle and Fibre Toxicology 2007, 4:10.
26. Sushama K.S., Varghese A., Muraleedharan D., Menon V.P. Protective action of aspirin in experimental myocardial infarction induced by isoproterenol in rats and its effect on lipid peroxidation. Indian Journal of Experimental Biology 1990, 28:480-485.
27. van Berlo J.H., Maillet M., Molkentin J.D. Signaling effectors underlying pathologic growth and remodeling of the heart. Journal of Clinical Investigation 2013, 123:37-45.
28. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discovery Today 2005, 10:1451-1458.
29. Yang H., Sun C., Fan Z., Tian X., Yan L., Du L., Liu Y., Chen C., Liang X.J., Anderson G.J., Keelan J.A., Zhao Y., Nie G. Effects of gestational age and surface modification on materno-fetal transfer of nanoparticles in murine pregnancy. Science Reports 2012, 2:847.